By the time you're done with this area you should accept a acceptable abstraction of the science abaft abscess and feel assured in how you would like to proceed.

Sunday, June 1, 2008

Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer (Presseportal)

Chicago and Darmstadt, Germany (ots/PRNewswire) - - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell ...

No comments: